Rapt Therapeutics Q3 net loss narrows as R&D costs drop

Reuters

Nov 06, 2025

Rapt <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q3 net loss narrows as R&D costs drop

Overview

Rapt Therapeutics Q3 net loss narrows to $17.6 mln from $18.4 mln in 2024
Company completed $250 mln public offering to strengthen balance sheet
R&D expenses decreased due to lower costs in several areas

Outlook

RAPT plans to report Phase 2 asthma trial results next year
Company to discuss CSU registrational pathway with FDA
RAPT's cash projected to fund operations to mid-2028

Result Drivers

PUBLIC OFFERING - Completed $250 mln public offering to strengthen balance sheet and fund operations to mid-2028

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS		-$0.65
Q3 Net Income		-$17.58 mln
Q3 Basic EPS		-$0.65
Q3 Operating Expenses		$19.37 mln
Q3 Operating Income		-$19.37 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for RAPT Therapeutics Inc is $60.00, about 52.9% above its November 5 closing price of $28.27

Press Release: ID:nGNX44xBsk

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2581010093"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581010093\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581010093?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 21:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581010093","market":"us","top_or_hot":-1,"title":"Rapt Therapeutics Q3 net loss narrows as R&D costs drop","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Rapt <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 net loss narrows as R&amp;D costs drop</title></head><body><p><span>Overview</span></p><ul><li><p>Rapt Therapeutics Q3 net loss narrows to $17.6 mln from $18.4 mln in 2024</p></li><li><p>Company completed $250 mln public offering to strengthen balance sheet</p></li><li><p>R&amp;D expenses decreased due to lower costs in several areas</p></li></ul><p><span>Outlook</span></p><ul><li><p>RAPT plans to report Phase 2 asthma trial results next year</p></li><li><p>Company to discuss CSU registrational pathway with FDA</p></li><li><p>RAPT's cash projected to fund operations to mid-2028</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PUBLIC OFFERING - Completed $250 mln public offering to strengthen balance sheet and fund operations to mid-2028</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.65</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$17.58 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.65</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$19.37 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$19.37 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for RAPT Therapeutics Inc is $60.00, about 52.9% above its November 5 closing price of $28.27</p></li></ul><p>Press Release: <span>ID:nGNX44xBsk</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rapt Therapeutics Q3 net loss narrows as R&D costs drop</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRapt Therapeutics Q3 net loss narrows as R&D costs drop\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 21:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Rapt <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 net loss narrows as R&amp;D costs drop</title></head><body><p><span>Overview</span></p><ul><li><p>Rapt Therapeutics Q3 net loss narrows to $17.6 mln from $18.4 mln in 2024</p></li><li><p>Company completed $250 mln public offering to strengthen balance sheet</p></li><li><p>R&amp;D expenses decreased due to lower costs in several areas</p></li></ul><p><span>Outlook</span></p><ul><li><p>RAPT plans to report Phase 2 asthma trial results next year</p></li><li><p>Company to discuss CSU registrational pathway with FDA</p></li><li><p>RAPT's cash projected to fund operations to mid-2028</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PUBLIC OFFERING - Completed $250 mln public offering to strengthen balance sheet and fund operations to mid-2028</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.65</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$17.58 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.65</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$19.37 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$19.37 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for RAPT Therapeutics Inc is $60.00, about 52.9% above its November 5 closing price of $28.27</p></li></ul><p>Press Release: <span>ID:nGNX44xBsk</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RAPT","symbol_name":"RAPT Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0QV:1","article_id":"2581010093","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581010093","pubTimestamp":1762434702,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Rapt Therapeutics Q3 net loss narrows as R&D costs dropOverviewRapt Therapeutics Q3 net loss narrows to $17.6 mln from $18.4 mln in 2024Company completed $250 mln public offering to strengthen balance","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RAPT":"RAPT Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"随着研发成本下降，Rapt Therapeutics第三季度净亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RAPT":0.9},"content_text":"Rapt Therapeutics Q3 net loss narrows as R&D costs dropOverviewRapt Therapeutics Q3 net loss narrows to $17.6 mln from $18.4 mln in 2024Company completed $250 mln public offering to strengthen balance sheetR&D expenses decreased due to lower costs in several areasOutlookRAPT plans to report Phase 2 asthma trial results next yearCompany to discuss CSU registrational pathway with FDARAPT's cash projected to fund operations to mid-2028Result DriversPUBLIC OFFERING - Completed $250 mln public offering to strengthen balance sheet and fund operations to mid-2028Key DetailsMetricBeat/MissActualConsensus EstimateQ3 EPS-$0.65Q3 Net Income-$17.58 mlnQ3 Basic EPS-$0.65Q3 Operating Expenses$19.37 mlnQ3 Operating Income-$19.37 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for RAPT Therapeutics Inc is $60.00, about 52.9% above its November 5 closing price of $28.27Press Release: ID:nGNX44xBskFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}